Blinatumomab 2023 global sales revenue?

How much revenue did blinatumomab generate worldwide in 2023?

Blinatumomab (marketed by Amgen/partnered brands under the Blincyto name in many regions) generated about $1.2 billion in global sales revenue in 2023. [1]

Where does that figure come from, and how reliable is it?

The 2023 global sales number above is reported as part of DrugPatentWatch.com’s drug sales tracking. [1]

Is 2023 revenue the same as net sales in the US and EU combined?

The figure is a global sales total, so it is intended to reflect combined performance across key markets rather than US-only or Europe-only topline. [1]

What drug is blinatumomab usually sold under?

Blinatumomab is the generic name for the product commonly known as Blincyto in multiple markets. [1]

Sources

[1] https://www.drugpatentwatch.com/patent/bilinatumomab/